Skip to main content
Equibles
COYA logo

COYA · Coya Therapeutics, Inc.

Track COYA — free

Use COYA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COYA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.38 -0.14 (-3.10%) At close · Sep 11
Rebalance outlook locked
Market Cap
$102.75M
Shares
23.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.38 Open$4.59 Day$4.37–4.66 52W close$3.78–7.36 Avg vol 30d111K Short int1.1M · 4.6% float · 11.5d Short vol50% Last earningsJun 2, 2026 DataDec 2022–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.02M
Trailing 12 months
Net income (TTM)
−$21.67M
Trailing 12 months
Revenue growth YoY
+49.0%
Year over year
Operating margin
-288.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+40.3%
Year over year · more shares
Price change (1Y)
-28.4%
Trailing year
Short interest
4.6%
Latest settlement · 11.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −7%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 17%
mid-range
Momentum
relative strength
Weak
1-month return −6%
trailing
6-month return +4%
trailing
YTD return −24%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.63% of float · ▲ +2.7% MoM · 11.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
55 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Fair
Revenue growth +124%
Y/Y
EPS growth −30%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 65%
annualized · 1-yr
Max drawdown −49%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
17% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.63% of float · ▲ +2.7% MoM · 11.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
55 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $4 · 17% Range high $7
vs 200-day avg -9% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COYA
Coya Therapeutics, Inc.
this stock
$102.75M -24.5% +123.6% — 4.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
55
% held
33.4%
Net QoQ
-361.5K sh
Top holder
DME Capital Management, LP
Held Float
View
Held by Funds
Fund positions
20
View
Short & Settlement
Short Interest Rising
Shares short
1.1M
Days to cover
11.5d
Change
+28.2K sh
View
Short Volume
Short vol %
50%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
255
Value
$1.2K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.9M
Net income (FY)
$-21.2M
EPS diluted
$-1.27
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
14
View
Exempt Offerings
Offering
$10.0M
Filed
Oct 28, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 2, 2026
View
Investor Relations
Latest news
Coya Therapeutics Announces Publi…
Published
Sep 8, 2026
View

Performance

5D 20D 120D MTD YTD
COYA -3.7% -6.2% +4.0% -4.0% -24.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -2.6% -4.5% -13.8% -3.6% -36.6%
Key facts CIK 1835022 CUSIP 22407B108 13F (30d) 32 filings 32 filers Visit website Investor relations